Guardant Health (NASDAQ:GH) Director Sells $20,300.00 in Stock

Key Points

• Guardant Health Director Musa Tariq sold 116 shares for approximately $20,300, reducing his holdings by 1% to 11,449 shares. The transaction was conducted under a pre-arranged Rule 10b5-1 trading plan.
• Guardant Health shares rose 4.7% to $183.10, near a new one-year high. The company reported second-quarter revenue growth of 44.3% to $334.98 million and a narrower-than-expected loss.
• Wall Street maintains a broadly positive outlook, with a consensus “Moderate Buy” rating and an average price target of $188.12; however, additional insider sales may raise some profit-taking concerns.

Guardant Health, Inc. (NASDAQ:GH - Get Free Report) Director Musa Tariq sold 116 shares of the company's stock in a transaction that occurred on Wednesday, September 16th. The shares were sold at an average price of $175.00, for a total value of $20,300.00. Following the completion of the transaction, the director directly owned 11,449 shares of the company's stock, valued at $2,003,575. This represents a 1.00% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Musa Tariq also recently made the following trade(s):

• On Monday, August 17th, Musa Tariq sold 116 shares of Guardant Health stock. The shares were sold at an average price of $156.45, for a total transaction of $18,148.20.
• On Monday, June 22nd, Musa Tariq sold 1,951 shares of Guardant Health stock. The stock was sold at an average price of $131.16, for a total transaction of $255,893.16.

Guardant Health Trading Up 4.7%

GH traded up $8.20 during trading on Thursday, reaching $183.10. 1,858,277 shares of the company's stock were exchanged, compared to its average volume of 2,252,181. Guardant Health, Inc. has a one year low of $55.38 and a one year high of $183.51. The firm has a fifty day moving average price of $160.33 and a two-hundred day moving average price of $126.47. The stock has a market capitalization of $24.57 billion, a PE ratio of -52.46 and a beta of 1.57.

Guardant Health (NASDAQ:GH - Get Free Report) last released its quarterly earnings results on Thursday, July 30th. The company reported ($0.42) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.76) by $0.34. The business had revenue of $334.98 million for the quarter, compared to the consensus estimate of $314.23 million. Guardant Health's revenue was up 44.3% on a year-over-year basis. During the same period in the previous year, the business posted ($0.44) EPS. Sell-side analysts expect that Guardant Health, Inc. will post -2.98 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several brokerages have commented on GH. Barclays lifted their target price on Guardant Health from $150.00 to $200.00 and gave the stock an "overweight" rating in a report on Friday, July 31st. Weiss Ratings restated a "sell (d-)" rating on shares of Guardant Health in a research report on Friday, July 17th. Guggenheim lifted their price objective on Guardant Health from $160.00 to $190.00 and gave the stock a "buy" rating in a research note on Thursday, July 16th. BTIG Research reiterated a "buy" rating and issued a $195.00 target price on shares of Guardant Health in a report on Wednesday, September 2nd. Finally, Stifel Nicolaus increased their target price on shares of Guardant Health from $130.00 to $180.00 and gave the company a "buy" rating in a research report on Friday, July 31st. One equities research analyst has rated the stock with a Strong Buy rating, twenty-four have issued a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Guardant Health currently has a consensus rating of "Moderate Buy" and a consensus price target of $188.12.

Institutional Trading of Guardant Health

A number of large investors have recently bought and sold shares of GH. Allworth Financial LP increased its holdings in Guardant Health by 12.4% in the second quarter. Allworth Financial LP now owns 1,072 shares of the company's stock worth $161,000 after purchasing an additional 118 shares in the last quarter. GAMMA Investing LLC grew its position in shares of Guardant Health by 14.5% during the 2nd quarter. GAMMA Investing LLC now owns 965 shares of the company's stock worth $145,000 after buying an additional 122 shares during the period. First Pacific Financial grew its position in shares of Guardant Health by 33.1% during the 1st quarter. First Pacific Financial now owns 559 shares of the company's stock worth $52,000 after buying an additional 139 shares during the period. ABS Investment Management LLC bought a new stake in shares of Guardant Health in the 2nd quarter valued at $345,069,000. Finally, MCF Advisors LLC lifted its position in shares of Guardant Health by 755.0% during the 2nd quarter. MCF Advisors LLC now owns 171 shares of the company's stock valued at $26,000 after acquiring an additional 151 shares during the period. 92.60% of the stock is currently owned by institutional investors and hedge funds.

Key Stories Impacting Guardant Health

Here are the key news stories impacting Guardant Health this week:

• Positive Sentiment: Guardant Health was described as nearing a technical buy point as its sales outlook brightened, supporting investor confidence in continued revenue growth. Guardant Health Nears Buy Point As Sales Outlook Brightens
• Positive Sentiment: A comparison of second-quarter testing and diagnostics companies highlighted Guardant Health’s strong performance. The company’s revenue rose 44.3% year over year to approximately $335 million and exceeded analyst expectations, while its quarterly loss was narrower than forecast. Testing & diagnostics services stocks Q2 results: Benchmarking Guardant Health
• Positive Sentiment: The stock reached a new one-year high, reflecting strong momentum and investor demand following its recent rally. The move could attract additional momentum-oriented buyers, though it also raises the risk of profit-taking. Guardant Health Reaches New 1-Year High - What’s Next?
• Neutral Sentiment: Director Musa Tariq sold 116 shares for about $20,300, reducing his position by 1%. The transaction was executed under a pre-arranged Rule 10b5-1 plan, making it a limited and less concerning signal. SEC Form 4 filing
• Negative Sentiment: Several insiders reported sales: Director Alex M. Azar II sold 826 shares for approximately $144,550, Director Steve Krognes sold 6,674 shares for roughly $1.17 million, and CTO Darya Chudova sold 7,738 shares for about $1.38 million. The transactions reduced their holdings substantially and could raise profit-taking concerns, although the sales were disclosed through SEC filings and some were conducted under pre-arranged plans. Insider sale SEC filing

About Guardant Health

Guardant Health, Inc NASDAQ: GH is a precision oncology company that develops blood-based diagnostic tests designed to help detect cancer, guide treatment decisions and monitor patients over time. Its liquid biopsy technologies analyze tumor-related signals in blood, reducing the need for tissue biopsies in certain clinical and research settings.

The company's products include Guardant360 tests, which profile advanced cancers and can help identify potentially actionable genomic alterations; Guardant Reveal, which is used to assess residual disease and recurrence risk; and Guardant Shield, a blood-based screening test for colorectal cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.